{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T10:50:24Z","timestamp":1768992624769,"version":"3.49.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-025-04193-z","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T10:56:45Z","timestamp":1744109805000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety assessment of apremilast: real-world adverse event analysis from the FAERS database"],"prefix":"10.1007","volume":"317","author":[{"given":"Landong","family":"Ren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaidi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengxiang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiashu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"issue":"7","key":"4193_CR1","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s40265-014-0218-4","volume":"74","author":"RM Poole","year":"2014","unstructured":"Poole RM, Ballantyne AD (2014) Apremilast: first global approval. Drugs 74(7):825\u2013837","journal-title":"Drugs"},{"issue":"2","key":"4193_CR2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40265-019-01253-3","volume":"80","author":"ED Deeks","year":"2020","unstructured":"Deeks ED (2020) Apremilast: A review in oral ulcers of Behcet\u2019s disease. Drugs 80(2):181\u2013188","journal-title":"Drugs"},{"issue":"6","key":"4193_CR3","doi-asserted-by":"crossref","first-page":"e14261","DOI":"10.1111\/dth.14261","volume":"33","author":"D Nassim","year":"2020","unstructured":"Nassim D et al (2020) Apremilast in dermatology: A review of literature. Dermatol Ther 33(6):e14261","journal-title":"Dermatol Ther"},{"issue":"1","key":"4193_CR4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s40257-017-0302-0","volume":"19","author":"T Torres","year":"2018","unstructured":"Torres T, Puig L (2018) Apremilast: A novel oral treatment for psoriasis and psoriatic arthritis. Am J Clin Dermatol 19(1):23\u201332","journal-title":"Am J Clin Dermatol"},{"issue":"10281","key":"4193_CR5","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"CEM Griffiths","year":"2021","unstructured":"Griffiths CEM et al (2021) Psoriasis Lancet 397(10281):1301\u20131315","journal-title":"Psoriasis Lancet"},{"issue":"9","key":"4193_CR6","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1080\/17425255.2016.1206886","volume":"12","author":"L Bianchi","year":"2016","unstructured":"Bianchi L et al (2016) Pharmacodynamic assessment of Apremilast for the treatment of moderate-to-severe plaque psoriasis. Expert Opin Drug Metab Toxicol 12(9):1121\u20131128","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"4193_CR7","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1093\/rheumatology\/keab449","volume":"61","author":"AF Wells","year":"2022","unstructured":"Wells AF et al (2022) Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naive patients. Rheumatology (Oxford) 61(3):1035\u20131043","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"4193_CR8","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s12325-023-02468-3","volume":"40","author":"P Cetkovska","year":"2023","unstructured":"Cetkovska P et al (2023) Apremilast use in severe psoriasis: Real-World data from central and Eastern Europe. Adv Ther 40(4):1787\u20131802","journal-title":"Adv Ther"},{"issue":"4","key":"4193_CR9","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s40265-017-0709-1","volume":"77","author":"GM Keating","year":"2017","unstructured":"Keating GM (2017) Apremilast: A review in psoriasis and psoriatic arthritis. Drugs 77(4):459\u2013472","journal-title":"Drugs"},{"issue":"6","key":"4193_CR10","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/bjd.14164","volume":"173","author":"C Paul","year":"2015","unstructured":"Paul C et al (2015) Efficacy and safety of Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol 173(6):1387\u20131399","journal-title":"Br J Dermatol"},{"issue":"1","key":"4193_CR11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jaad.2021.07.040","volume":"86","author":"L Stein Gold","year":"2022","unstructured":"Stein Gold L et al (2022) Efficacy and safety of Apremilast in patients with mild-to-moderate plaque psoriasis: results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 86(1):77\u201385","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"4193_CR12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","volume":"73","author":"K Papp","year":"2015","unstructured":"Papp K et al (2015) Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and safety trial evaluating the effects of Apremilast in psoriasis [ESTEEM] 1). J Am Acad Dermatol 73(1):37\u201349","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"4193_CR13","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1111\/j.1468-3083.2011.04429.x","volume":"27","author":"KA Papp","year":"2013","unstructured":"Papp KA et al (2013) Efficacy and safety of Apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. J Eur Acad Dermatol Venereol 27(3):e376\u2013e383","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4193_CR14","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2147\/CLEP.S365513","volume":"14","author":"Y Shu","year":"2022","unstructured":"Shu Y et al (2022) A Real-World disproportionality analysis of Olaparib: data mining of the public version of FDA adverse event reporting system. Clin Epidemiol 14:789\u2013802","journal-title":"Clin Epidemiol"},{"key":"4193_CR15","doi-asserted-by":"crossref","first-page":"1420126","DOI":"10.3389\/fphar.2024.1420126","volume":"15","author":"S Li","year":"2024","unstructured":"Li S et al (2024) Real-world pharmacovigilance analysis of galsulfase: a study based on the FDA adverse event reporting system (FAERS) database. Front Pharmacol 15:1420126","journal-title":"Front Pharmacol"},{"key":"4193_CR16","doi-asserted-by":"crossref","first-page":"1368763","DOI":"10.3389\/fphar.2024.1368763","volume":"15","author":"Z Li","year":"2024","unstructured":"Li Z et al (2024) Post-marketing safety evaluation of lurbinectedin: a pharmacovigilance analysis based on the FAERS database. Front Pharmacol 15:1368763","journal-title":"Front Pharmacol"},{"issue":"7","key":"4193_CR17","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2165\/00002018-200730070-00009","volume":"30","author":"P Mozzicato","year":"2007","unstructured":"Mozzicato P (2007) Standardised MedDRA queries: their role in signal detection. Drug Saf 30(7):617\u2013619","journal-title":"Drug Saf"},{"issue":"9","key":"4193_CR18","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s40264-021-01086-8","volume":"44","author":"A Mascolo","year":"2021","unstructured":"Mascolo A et al (2021) Immune checkpoint inhibitors and cardiotoxicity: an analysis of spontaneous reports in eudravigilance. Drug Saf 44(9):957\u2013971","journal-title":"Drug Saf"},{"issue":"1","key":"4193_CR19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP et al (2002) A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 11(1):3\u201310","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"4193_CR20","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","volume":"72","author":"JL Montastruc","year":"2011","unstructured":"Montastruc JL et al (2011) Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol 72(6):905\u2013908","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"4193_CR21","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7150\/ijms.7967","volume":"11","author":"T Sakaeda","year":"2014","unstructured":"Sakaeda T et al (2014) Commonality of drug-associated adverse events detected by 4 commonly used data mining algorithms. Int J Med Sci 11(5):461\u2013465","journal-title":"Int J Med Sci"},{"issue":"3","key":"4193_CR22","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/bjd.15021","volume":"176","author":"DA Springate","year":"2017","unstructured":"Springate DA et al (2017) Incidence, prevalence and mortality of patients with psoriasis: a U.K. population-based cohort study. Br J Dermatol 176(3):650\u2013658","journal-title":"Br J Dermatol"},{"issue":"4","key":"4193_CR23","doi-asserted-by":"crossref","first-page":"400","DOI":"10.2340\/00015555-3130","volume":"99","author":"E Pezzolo","year":"2019","unstructured":"Pezzolo E et al (2019) Psoriasis incidence and lifetime prevalence: suggestion for a higher mortality rate in older Age-classes among psoriatic patients compared to the general population in Italy. Acta Derm Venereol 99(4):400\u2013403","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"4193_CR24","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.jaad.2017.09.067","volume":"78","author":"A Ighani","year":"2018","unstructured":"Ighani A et al (2018) Short-term reasons for withdrawal and adverse events associated with Apremilast therapy for psoriasis in real-world practice compared with in clinical trials: A multicenter retrospective study. J Am Acad Dermatol 78(4):801\u2013803","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"4193_CR25","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/1346-8138.17270","volume":"51","author":"M Ohtsuki","year":"2024","unstructured":"Ohtsuki M et al (2024) Safety and effectiveness of Apremilast in Japanese patients with psoriatic disease: results of a post-marketing surveillance study. J Dermatol 51(7):950\u2013963","journal-title":"J Dermatol"},{"issue":"2","key":"4193_CR26","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/1203475416676030","volume":"21","author":"JN Mayba","year":"2017","unstructured":"Mayba JN, Gooderham MJ (2017) Real-World experience with Apremilast in treating psoriasis. J Cutan Med Surg 21(2):145\u2013151","journal-title":"J Cutan Med Surg"},{"issue":"3","key":"4193_CR27","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1177\/1203475418755982","volume":"22","author":"A Ighani","year":"2018","unstructured":"Ighani A et al (2018) Efficacy and safety of Apremilast monotherapy for moderate to severe psoriasis: retrospective study. J Cutan Med Surg 22(3):290\u2013296","journal-title":"J Cutan Med Surg"},{"key":"4193_CR28","doi-asserted-by":"crossref","unstructured":"Conti A, Tiberio R (2022) Real-world experience on the efficacy and safety of apremilast in bio-naive patients with moderate plaque psoriasis. J Eur Acad Dermatol Venereol 36(11):1900","DOI":"10.1111\/jdv.18509"},{"issue":"4","key":"4193_CR29","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1177\/1203475417748886","volume":"22","author":"A Langley","year":"2018","unstructured":"Langley A, Beecker J (2018) Management of common side effects of Apremilast. J Cutan Med Surg 22(4):415\u2013421","journal-title":"J Cutan Med Surg"},{"key":"4193_CR30","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3389\/fphar.2018.01048","volume":"9","author":"H Li","year":"2018","unstructured":"Li H, Zuo J, Tang W (2018) Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases. Front Pharmacol 9:1048","journal-title":"Front Pharmacol"},{"issue":"12","key":"4193_CR31","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.bcp.2012.01.001","volume":"83","author":"P Schafer","year":"2012","unstructured":"Schafer P (2012) Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol 83(12):1583\u20131590","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"4193_CR32","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1586\/1744666X.2016.1134319","volume":"12","author":"A Chiricozzi","year":"2016","unstructured":"Chiricozzi A et al (2016) A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: Apremilast. Expert Rev Clin Immunol 12(3):237\u2013249","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"4193_CR33","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrd4228","volume":"13","author":"DH Maurice","year":"2014","unstructured":"Maurice DH et al (2014) Advances in targeting Cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov 13(4):290\u2013314","journal-title":"Nat Rev Drug Discov"},{"key":"4193_CR34","doi-asserted-by":"crossref","unstructured":"Crocetti L et al (2022) An overview of PDE4 inhibitors in clinical trials: 2010 to early 2022. Molecules, 27(15)","DOI":"10.3390\/molecules27154964"},{"issue":"5","key":"4193_CR35","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s40259-015-0144-3","volume":"29","author":"M Gooderham","year":"2015","unstructured":"Gooderham M, Papp K (2015) Selective phosphodiesterase inhibitors for psoriasis: focus on Apremilast. BioDrugs 29(5):327\u2013339","journal-title":"BioDrugs"},{"issue":"3","key":"4193_CR36","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.annder.2017.01.004","volume":"144","author":"JL Schmutz","year":"2017","unstructured":"Schmutz JL (2017) [Apremilast: beware of suicidal ideation and behaviour]. Ann Dermatol Venereol 144(3):243\u2013244","journal-title":"Ann Dermatol Venereol"},{"issue":"8","key":"4193_CR37","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/jdv.16231","volume":"34","author":"C Vasilakis-Scaramozza","year":"2020","unstructured":"Vasilakis-Scaramozza C et al (2020) The risk of treated anxiety and treated depression among patients with psoriasis and psoriatic arthritis treated with Apremilast compared to biologics, DMARDs and corticosteroids: a cohort study in the united States marketscan database. J Eur Acad Dermatol Venereol 34(8):1755\u20131763","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"4193_CR38","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/acr2.11156","volume":"2","author":"PJ Mease","year":"2020","unstructured":"Mease PJ et al (2020) Long-Term safety and tolerability of Apremilast versus placebo in psoriatic arthritis: A pooled safety analysis of three phase III, randomized, controlled trials. ACR Open Rheumatol 2(8):459\u2013470","journal-title":"ACR Open Rheumatol"},{"key":"4193_CR39","doi-asserted-by":"crossref","first-page":"111065","DOI":"10.1016\/j.biopha.2020.111065","volume":"137","author":"X Wang","year":"2021","unstructured":"Wang X et al (2021) Dysregulation of the gut-brain-skin axis and key overlapping inflammatory and immune mechanisms of psoriasis and depression. Biomed Pharmacother 137:111065","journal-title":"Biomed Pharmacother"},{"issue":"12","key":"4193_CR40","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1111\/jdv.14460","volume":"31","author":"J Koo","year":"2017","unstructured":"Koo J et al (2017) Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression. J Eur Acad Dermatol Venereol 31(12):1999\u20132009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4193_CR41","doi-asserted-by":"crossref","first-page":"699848","DOI":"10.3389\/fimmu.2021.699848","volume":"12","author":"E Zafiriou","year":"2021","unstructured":"Zafiriou E et al (2021) Depression and obesity in patients with psoriasis and psoriatic arthritis: is IL-17-Mediated immune dysregulation the connecting link?? Front Immunol 12:699848","journal-title":"Front Immunol"},{"issue":"11","key":"4193_CR42","doi-asserted-by":"crossref","first-page":"adv00609","DOI":"10.2340\/actadv.v101.565","volume":"101","author":"S Holsken","year":"2021","unstructured":"Holsken S et al (2021) Common fundamentals of psoriasis and depression. Acta Derm Venereol 101(11):adv00609","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"4193_CR43","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s40257-022-00703-1","volume":"23","author":"M Gyldenlove","year":"2022","unstructured":"Gyldenlove M et al (2022) Combination therapy with Apremilast and biologics for psoriasis: A systematic review. Am J Clin Dermatol 23(5):605\u2013613","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"4193_CR44","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1177\/1203475416631328","volume":"20","author":"M AbuHilal","year":"2016","unstructured":"AbuHilal M, Walsh S, Shear N (2016) Use of Apremilast in combination with other therapies for treatment of chronic plaque psoriasis: A retrospective study. J Cutan Med Surg 20(4):313\u2013316","journal-title":"J Cutan Med Surg"},{"issue":"3","key":"4193_CR45","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/rheumatology\/keab474","volume":"61","author":"LD Ferguson","year":"2022","unstructured":"Ferguson LD et al (2022) Effect of the phosphodiesterase 4 inhibitor Apremilast on cardiometabolic outcomes in psoriatic disease-results of the immune metabolic associations in psoriatic arthritis study. Rheumatology (Oxford) 61(3):1026\u20131034","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"4193_CR46","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1001\/jamadermatol.2022.3862","volume":"158","author":"JM Gelfand","year":"2022","unstructured":"Gelfand JM et al (2022) Association of Apremilast with vascular inflammation and cardiometabolic function in patients with psoriasis: the VIP-A phase 4, Open-label, nonrandomized clinical trial. JAMA Dermatol 158(12):1394\u20131403","journal-title":"JAMA Dermatol"},{"issue":"5","key":"4193_CR47","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1177\/1203475415586332","volume":"19","author":"P Fleming","year":"2015","unstructured":"Fleming P et al (2015) The relationship of obesity with the severity of psoriasis: A systematic review. J Cutan Med Surg 19(5):450\u2013456","journal-title":"J Cutan Med Surg"},{"issue":"3","key":"4193_CR48","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1093\/rheumatology\/keac403","volume":"62","author":"SS Zhao","year":"2023","unstructured":"Zhao SS et al (2023) Association between psoriatic disease and lifestyle factors and comorbidities: cross-sectional analysis and Mendelian randomization. Rheumatology (Oxford) 62(3):1272\u20131285","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"4193_CR49","doi-asserted-by":"crossref","first-page":"492","DOI":"10.2340\/00015555-0711","volume":"89","author":"K Wolk","year":"2009","unstructured":"Wolk K et al (2009) Excessive body weight and smoking associates with a high risk of onset of plaque psoriasis. Acta Derm Venereol 89(5):492\u2013497","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"4193_CR50","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1517\/14712598.2014.900541","volume":"14","author":"N Al-Mutairi","year":"2014","unstructured":"Al-Mutairi N, Nour T (2014) The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial. Expert Opin Biol Ther 14(6):749\u2013756","journal-title":"Expert Opin Biol Ther"},{"issue":"8","key":"4193_CR51","first-page":"786","volume":"14","author":"R McAndrew","year":"2015","unstructured":"McAndrew R, Levin E, Koo J (2015) Emerging oral immunomodulators for the treatment of psoriasis: A review of phase III clinical trials for Apremilast and Tofacitinib. J Drugs Dermatol 14(8):786\u2013792","journal-title":"J Drugs Dermatol"},{"issue":"12","key":"4193_CR52","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s40265-015-0439-1","volume":"75","author":"ED Deeks","year":"2015","unstructured":"Deeks ED (2015) Apremilast: A review in psoriasis and psoriatic arthritis. Drugs 75(12):1393\u20131403","journal-title":"Drugs"},{"issue":"2","key":"4193_CR53","first-page":"221","volume":"17","author":"L Stein Gold","year":"2018","unstructured":"Stein Gold L et al (2018) Efficacy and safety of Apremilast in Systemic- and Biologic-Naive patients with moderate plaque psoriasis: 52-Week results of UNVEIL. J Drugs Dermatol 17(2):221\u2013228","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"4193_CR54","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1007\/s13555-022-00747-5","volume":"12","author":"Y Okubo","year":"2022","unstructured":"Okubo Y et al (2022) Efficacy and safety of Apremilast in the treatment of patients with Mild-to-Moderate psoriasis in Japan: results from PROMINENT, A phase 3b, Open-Label, Single-Arm study. Dermatol Ther (Heidelb) 12(6):1469\u20131480","journal-title":"Dermatol Ther (Heidelb)"},{"key":"4193_CR55","doi-asserted-by":"crossref","first-page":"119563","DOI":"10.1016\/j.lfs.2021.119563","volume":"278","author":"CA Arcaro","year":"2021","unstructured":"Arcaro CA et al (2021) Phosphodiesterase 4 Inhibition restrains muscle proteolysis in diabetic rats by activating PKA and EPAC\/Akt effectors and inhibiting FoxO factors. Life Sci 278:119563","journal-title":"Life Sci"},{"issue":"3","key":"4193_CR56","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/mus.22066","volume":"44","author":"EC Lira","year":"2011","unstructured":"Lira EC et al (2011) Phosphodiesterase-4 Inhibition reduces proteolysis and atrogenes expression in rat skeletal muscles. Muscle Nerve 44(3):371\u2013381","journal-title":"Muscle Nerve"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-04193-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-025-04193-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-04193-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T10:57:13Z","timestamp":1744109833000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-025-04193-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4193"],"URL":"https:\/\/doi.org\/10.1007\/s00403-025-04193-z","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]},"assertion":[{"value":"17 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"684"}}